A significant challenge in treating ALK-positive NSCLC is the extensive mutational variability of the eml4-alk fusion gene and the diversity of amino acid substitutions within the tyrosine kinase domain of the ALK protein (Elshatlawy et al., 2023). Here, ALK is linked to non-small cell lung carcinoma.